ONCODES.PREC.MED. EO-34 (ZR8) — Working Capital to Net Assets Ratio
ONCODES.PREC.MED. EO-34 (ZR8) has a Working Capital to Net Assets ratio of -1178.1% as of December 2024. Working capital of €5.06 Million (current assets of €8.67 Million minus current liabilities of €3.61 Million) is measured against net assets of €-429.39K. A higher ratio indicates strong short-term liquidity financed by the equity base. See ZR8 days of operational coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ONCODES.PREC.MED. EO-34 Working Capital to Net Assets (2021–2024)
This chart shows how ONCODES.PREC.MED. EO-34's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at -1178.1%, reflecting working capital of €5.06 Million against net assets of €-429.39K EUR. For the complete balance sheet picture, see how large is ONCODES.PREC.MED. EO-34's balance sheet.
Annual Working Capital to Net Assets for ONCODES.PREC.MED. EO-34 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for ONCODES.PREC.MED. EO-34 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of ONCODES.PREC.MED. EO-34 to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -1178.1% | €5.06 Million | €-429.39K | €8.67 Million | €3.61 Million | ▼ -1456.9 pp |
| 2023 | 278.8% | €10.29 Million | €3.69 Million | €14.40 Million | €4.11 Million | ▲ +173.2 pp |
| 2022 | 105.6% | €12.45 Million | €11.78 Million | €16.41 Million | €3.96 Million | ▼ -21.0 pp |
| 2021 | 126.6% | €5.32 Million | €4.20 Million | €6.53 Million | €1.21 Million | — |